JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.74, sa.9, ss.1167-1176, 2019 (SCI-Expanded)
BACKGROUND Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined.